Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers Squibb shares have plummeted due to concerns about patent expirations and growth prospects. BMY stock is currently trading near its 200-week moving average, which historically has been a good buying opportunity. The company has made acquisitions and has a pipeline of candidates to offset patent expirations and drive future growth.

Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

High-yield dividend stocks, on balance, are incredible value creators for long-term investors. Bristol Myers Squibb's yield has swelled to 5.6% this year, creating a compelling opportunity for patient investors.

This Unpopular Dividend Stock Is a Buy

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMERGENT--Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting.

Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).

Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo

Sanofi

A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million.

Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries.

Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection LONDON , May 22, 2024 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round. The additional investment from Bristol Myers Squibb will enable NeoPhore to explore novel biology associated with the DNA mismatch repair ('MMR') pathway in cancer, as well as further progress its pre-clinical studies and deliver a candidate drug in 2025.

NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

Comerica

Dominion Energy

ONEOK

Rio Tinto plc Sponsored

Verizon

Top Wall Street Strategist Sees 500 Point S&P 500 Drop – Buy 6 Passive Income Dividend Stocks Now

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #MentalHealthMonth--Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign.

Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign

BorgWarner

Citigroup

Since the bull market began in November 2022, growth stocks have outperformed value by a significant margin. Nevertheless, value S&P 500 sectors like financials and utilities have led over the past two months as the market has broadened out.

3 Bargain Stocks to Buy Now: May 2024

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivo and hyaluronidase).

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

Alexander & Baldwin

Enbridge

OneMain Hld

Vici Properties

Dividend growth stocks can provide reliable cash flows and help to build long-term wealth for income investors. Every month we look at screening dividend stocks based on safety, growth, and consistency, which can help identify worthwhile investments. We look at a list of 25 of the top yielding based on these metrics, then take a brief look at the 5 of these top positions.

May's 5 Dividend Growth Stocks With 5.49%+ Yields

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EADV--New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis.

New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

Absci Corp

Eli Lilly

Novo Nordisk

Novartis

Pfizer

Schrodinger 

It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?

7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma.

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Celgene

Bristol-Myers Squibb Company (NYSE:BMY ) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I'm Geoff Meacham. I'm the senior biopharma analyst, and I have Charlie from my team on stage with me as well.

Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript

The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that has returned or has not responded to prior treatments.

US FDA approves expanded use of Bristol's cancer cell therapy

Duke Energy

Ennis

Give someone a dividend and you pay them that day but teach them to capture the dividend and you provide investment income for life! Executing a capture-the-dividend trade entails buying the stock before the ex-date so you are the shareholder of record.

Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders

Bristol-Myers Squibb Company. (NYSE:BMY ) Guggenheim Securities Radiopharmaceuticals Day May 13, 2024 11:00 AM ET Company Participants Ben Hickey - President RayzeBio, Head of Mirati Conference Call Participants Unidentified Analyst Alright, Ben, let's continue here with Ben Hickey now from Bristol.

Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Datadog

Starbucks

Starbucks is still seeing strong traffic, despite its earnings miss. Datadog's longer-term prospects look better than its short-term hiccup.

Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip

Expenses related to acquisitions recently weighed down Bristol Myers' earnings results. The company, however, still generates strong free cash flow.

Is Bristol Myers' Dividend in Danger?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #NSCLC--Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial.

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

CVS Health

TripAdvisor

Savvy stock investors often look for bargains using the Relative Strength Index (RSI). This technical tool evaluates a stock's performance over the last 14 days and assigns a value from 0 to 100.

News for Bristol-Myers Stock (BMY)